Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. - Wikidata - wikimedia - TriplyDB

Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.

Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.

http://www.wikidata.org/entity/Q35091593

about

Mucormycosis, pseudallescheriasis, and other uncommon mold infections Advances in the treatment of invasive neonatal candidiasis In vivo efficacy of a synthetic coumarin derivative in a murine model of aspergillosis Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.Antifungal pharmacokinetics and pharmacodynamics Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens Penetration of amphotericin B lipid formulations into pleural effusion.Invasive fungal infections in acute leukemia.Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Safety of aerosolized amphotericin B.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations.Tissue penetration of antifungal agents.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Amphotericin B use in children: conventional and lipid-based formulations.Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus.Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice.Amphotericin B concentrations in healthy mallard ducks (Anas platyrhynchos) following a single intratracheal dose of liposomal amphotericin B using an atomizer.Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia.Leishmaniasis in humans: drug or vaccine therapy?

P2860

Q24603297-B005C7C8-9E40-498D-8F04-B5E8D92903F0 Q27022585-A238AED5-AD76-433E-9ABA-8259EBE0FDD5 Q28542402-452418D4-1D15-415C-9F32-B35F5E429917 Q34045435-B035DA29-E991-4F54-B1B8-D139B26164C7 Q34290097-4D49AA72-4469-4AB4-8256-3DBD4BFDD56E Q35385786-BB8B697A-64E0-4BE2-A61F-02E9B4A983A7 Q35663841-E66645C3-9F11-466C-97C8-6266CBEB7799 Q36276870-927F8999-AC0E-4829-9B72-AAC7A4263C2C Q36295392-913E5161-8A96-47C0-AFB4-3D028780220F Q36612597-A117ED6A-DA66-44BF-AD6D-671A6D7902A7 Q36868273-E320A2CD-F17C-48FB-A67E-DEBEB7DE7141 Q36945011-1BCB3851-EEDE-4982-9ED4-52720F735A8C Q36948094-71DFE5AB-ABAF-4D17-B713-B333D313F373 Q37409856-F71C43A6-27E1-4CF2-BBC8-9B7204E739B0 Q37544911-5278251A-E00E-4259-9600-6D0970214F46 Q37816399-A651E619-32A4-4F77-A439-BFC635FC551E Q37854727-36C2A8E5-58A9-412F-953C-99462BAE4F5F Q37925817-AE89E1BA-43C2-41AB-BF9C-15908DB700A7 Q37942644-8F6858C2-B984-48C0-A689-B33EE167380F Q38193337-7F50896D-0D8A-4F22-91D1-1C070E56F940 Q39661366-F1897461-C861-45C7-B3DD-DFA2D5383E25 Q40183751-AFF5E753-4384-4972-9FAE-DDF9B8380ECF Q41570433-3B54B5C4-E3B4-43B2-8127-950A1D45F4F8 Q41989595-E5570E9D-B378-4851-B5A5-98048FB99DDB Q42075610-693AA408-74D9-447C-AE2D-2F4A88A9E424 Q42277564-E4406298-1FED-4D41-B8A8-B1395770610F Q47556262-F3437544-BF60-4E86-9A1E-2EA8A1B995D3

P2860

Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.

http://www.wikidata.org/entity/Q35091593

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Compartmentalized intrapulmona ...... B and its lipid formulations.

@ast

Compartmentalized intrapulmona ...... B and its lipid formulations.

@en

type

label

Compartmentalized intrapulmona ...... B and its lipid formulations.

@ast

Compartmentalized intrapulmona ...... B and its lipid formulations.

@en

prefLabel

Compartmentalized intrapulmona ...... B and its lipid formulations.

@ast

Compartmentalized intrapulmona ...... B and its lipid formulations.

@en

P1433

Q35091593-428EDEFC-3810-40D3-AE96-68BB4D509FC2

P1476

Q35091593-D2906989-6577-444A-84A8-B91C6A35F2C2

P2093

Q35091593-50013745-07D9-4673-A6A4-53B10604A618

Q35091593-666C75B2-D89E-4BB9-BA3F-D629BB4C832E

Q35091593-7650F159-B301-4581-996F-612B2992214C

Q35091593-8F0E0512-1C06-4F85-B92D-B24720606865

Q35091593-ABD05B3F-2A06-435F-B84A-9A910856B144

Q35091593-AEAD1A91-BFE9-4CDF-AD4C-69574D1AC78D

Q35091593-CBB11E03-3771-4010-831C-D10E3C63D3DC

Q35091593-D22C3F30-95C3-4CA5-8922-F8953C23FBF8

Q35091593-DDA1EAD2-9010-413B-85AE-F7A146AFA777

Q35091593-DDD93004-92FA-4A64-9261-F6081F56F00B

P2860

Q35091593-09981E25-CD4B-447D-8F95-6DA4902CA35F

Q35091593-199AA1BA-01CB-4657-AA6A-DF39C51E61E1

Q35091593-1E90D2E0-1E79-4BA9-9807-87A0B3327E3E

Q35091593-2B29E3C4-6CB1-4367-884D-121FABE89EE4

Q35091593-50472AF5-B071-4BF8-AAD7-211AA3A4C989

Q35091593-51E682C9-5689-4287-8B96-6285B626C6FA

Q35091593-648A5D15-0B8F-423B-A0B8-E2FD31B7C4D3

Q35091593-65C80524-6B6B-481A-8966-82F8AF84754D

Q35091593-7635DC94-9DF1-4201-A195-23195AAD8E41

Q35091593-7A59AB64-FD55-4DFC-9CB5-859BE0A15682

P304

Q35091593-617F0F95-9E41-4125-82D4-C9ED4637EBE0

P31

Q35091593-4ED64792-651F-4BFA-8E25-28E2BD7ECF79

P356

Q35091593-24799170-5D88-4206-976C-1ECC766D4469

P407

Q35091593-308E75B5-A3E5-4FAA-BD62-585EDB76434B

P433

Q35091593-0769E797-F605-422A-BE42-FA48D04C18A3

P478

Q35091593-DD1FA3F5-E8DC-4E62-8956-11BB886DD30C

P577

Q35091593-4C3BC309-7229-40CE-AC83-854114CC1BD6

P698

Q35091593-59A52DA1-FAA5-4A96-94CB-AD6B60E997E9

P932

Q35091593-3EF1C1E4-F4A0-41C4-948A-6C947D2A524F

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Compartmentalized intrapulmona ...... B and its lipid formulations.

@en

P2093

Andreas H Groll

http://www.w3.org/2001/XMLSchema#string

Caron A Lyman

http://www.w3.org/2001/XMLSchema#string

Derek Armstrong

http://www.w3.org/2001/XMLSchema#string

Diana Mickiene

http://www.w3.org/2001/XMLSchema#string

John Bacher

http://www.w3.org/2001/XMLSchema#string

Raul M Alfaro

http://www.w3.org/2001/XMLSchema#string

Robert L Schaufele

http://www.w3.org/2001/XMLSchema#string

Ruta Petraitiene

http://www.w3.org/2001/XMLSchema#string

Thomas J Walsh

http://www.w3.org/2001/XMLSchema#string

Tin Sein

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies

Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis

Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.

Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits.

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.

Antifungal chemotherapy: advances and perspectives.

Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.

Clinical pharmacology of antifungal compounds.

Carrier effects on biological activity of amphotericin B.

P304

3418-3423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00241-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17005824

http://www.w3.org/2001/XMLSchema#string

P932

1610093

http://www.w3.org/2001/XMLSchema#string